Detalles de la búsqueda
1.
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
JAMA Oncol;
8(7): 1047-1052, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35552364
2.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
J Immunother Cancer;
9(7)2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34301809
3.
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.
Clin Cancer Res;
27(16): 4521-4530, 2021 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34083236
4.
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Cancer Discov;
10(8): 1158-1173, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32439653
5.
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
Future Oncol;
15(19): 2211-2225, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31074641
6.
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Clin Cancer Res;
25(9): 2717-2724, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30563931
7.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med;
379(8): 753-763, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30110579
8.
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Cancer Chemother Pharmacol;
80(6): 1161-1169, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29043412
9.
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat;
166(1): 327-328, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28884461
10.
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat;
165(2): 329-341, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28612225
11.
Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Br J Haematol;
178(1): 112-118, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28444784
12.
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Eur J Cancer;
76: 205-215, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28360015
13.
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Biol Blood Marrow Transplant;
23(6): 997-1004, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28285079
14.
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Blood;
127(13): 1656-65, 2016 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-26825712
15.
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol;
16(15): 1556-1568, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26482278
16.
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Lancet Oncol;
14(12): 1216-25, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24095299
17.
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
Cancer Chemother Pharmacol;
69(2): 523-31, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21874318
18.
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.
Invest New Drugs;
30(4): 1676-83, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21826439
19.
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Invest New Drugs;
30(6): 2294-302, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22072399
20.
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Clin Cancer Res;
17(15): 5132-9, 2011 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21558407